Clinical Trial Update: A Study in Cancer Patients to Evaluate the Effect of a Single Dose of NKTR-102 (Etirinotecan Pegol) on the QTc Interval and to Assess Pharmacokinetics and Safety [Phase 1]

View source ↗

Summary

This Phase 1 study evaluated the effect of a single dose of NKTR-102 (etirinotecan pegol) on QTc interval and assessed pharmacokinetics and safety in patients w…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cancer
• Solid Tumors

Drugs mentioned

• NKTR-102 (Etirinotecan Pegol) (etirinotecan pegol)

Snippet

Sponsor: Nektar Therapeutics | Conditions: Advanced Cancer, Metastatic Solid Tumors | Phase 1 | Status: COMPLETED